about
An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1DPhylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions.Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom.Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.The contribution of viral genotype to plasma viral set-point in HIV infectionIntercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in JapanAutomated analysis of phylogenetic clusters.Transmission network parameters estimated from HIV sequences for a nationwide epidemic.Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission ClustersA Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland.HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.A Phylogenetic Analysis of HIV-1 Sequences in Kiev: Findings among Key Populations.A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom.Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase.The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART)
P50
Q28471994-0CBCFA37-47CB-4B1B-8E2B-6BC213C91442Q28538687-F03AD609-11C2-4F7B-B317-450B59DC7FF1Q31172386-4A61B67F-7CAC-4E73-9AA2-CC447F8FD463Q33506612-F5CCA921-DEE2-49F2-AD74-376714039A7CQ33553109-66E8A1F9-FBB9-4A22-BD0B-261B9D9244D7Q33553778-1E8B5EF2-F0E5-45C9-8250-84BB62BE6310Q34059636-0D733FF7-3E6A-4B4D-89E7-D8CC383C3F85Q34493132-07C6A568-B89F-45EE-AA29-F800F941FBFCQ35238164-9DCDDAF6-3C84-4D50-B8B9-D4ABCD3A8D60Q36185311-3A935E1B-C55F-49DF-A1C4-C97236936F1FQ36745253-9BC41872-E7CD-43FB-BBC1-1C70DED8822EQ37264576-94FADE59-802C-47D0-A14A-F803F4F6CCA6Q38442212-00E08465-691B-44DB-A382-AF5579C0CBD4Q38748311-6586434A-6272-4C3C-980D-541E219484BDQ39275681-B14393B6-8BEE-4C63-AB4B-3BA0139452A4Q39422861-108CAE8C-DABC-4E6F-B23A-4215A2F1182CQ41216109-2D07F4CC-A7A5-40B6-B74D-034835157BEEQ42259952-BAAC85EE-F47A-4762-BCAE-EDFF307F88C0Q46328096-AB157617-84C8-49D1-BA82-D0963A814417Q50534874-6A0B9502-06FA-46B2-956D-66D7A0DF40BCQ50598265-39CF1E95-BDF2-49B1-9FFD-3DD722EFE428Q50622302-CEE63B2D-748A-40BE-8537-0405B4FFA795Q50697062-B1F0BBE0-C9C0-4AC3-B820-1FFD20C363B7Q59119603-A0A04339-E36B-4165-9D09-D8A5312353B4
P50
name
Esther Fearnhill
@en
Esther Fearnhill
@nl
type
label
Esther Fearnhill
@en
Esther Fearnhill
@nl
prefLabel
Esther Fearnhill
@en
Esther Fearnhill
@nl